Great post, Pippo. Nice to see you've been stepping up to the plate and hitting a few home runs! I can see that SPPI is in good hands and will have a wonderful trip/summer knowing there are soooo many knowledgeable longs on this MB. Toodle do
You are kinder to the little "fat man" than I am, Joe. (*~*) I will be leaving next week and prolly will not be around much until late Sept. Will check in when I can.......on the road again!
Have fun........love, live, laugh and enjoy and I'll do the same!! Looking forward to seeing SPPI in the 20's by the EOY and who knows, maybe we'll even get bought out while i"m gone.....ho ho ho!!!
Generic drug prices: Why their prices are suddenly surging. This is the topic you need to google, since it didn't come through like I had intended:
S'prise, s'prise......once generics are allowed to compete with the original version, the generic prices start going up!!! Perhaps SPPI could just lower their price for Fusilev and take away the generic market. Here's an interesting read about generics.....just google it::
For 30 years, generic medications helped make health care cheaper. Why is their cost surging?
Wonder how many lawsuits Sandoz will end up with their unstable version of Fusilev? Perhaps their logo will become "we'll put you out of your misery quicker than you could ever imagine'"
What purpose does he have in posting on this MB then?? Makes you wonder, doesn't it??!! Only thing I can think of is that some SHORT HF is paying him to post negative remarks about SPPI. Why in the world would one go to such lengths as to post on a MB that they don't even own any stock unless he's being paid or instructed to post negative things about SPPI. UNBELIEVABLE!!
We expect negative posts from shorts like, Bio, so what's the difference in we LONGS, who are believers, posting positive things? It's quite obvious who the shorts on this MB are!!
Oh me, oh my. BTW, it appears that CHK is ready to take a downward spill. As for SPPI, The Daytrader's Almanac says to stay short, so I expect we will be going down again tomorrow, but then since we're nothing more than a MANIPULATED stock at this point, nothing would surprise me in the least!!
Just a reminder of why some of us were given reasons to get excited about SPPI:
Gene Marcial Gene Marcial Contributor
I have an insider's take on Wall Street
Investing 9/09/2012 @ 8:00AM 18,500 views
Why This Tiny But Profitable Biotech May Be Gobbled Up By Big Pharma
Not many leaders in biotechnology get enough recognition for their dedication and hard-won achievements, probably because it takes so many years for their work to show solid results.
So it isn’t surprising that Dr. Rajesh Shrotriya is only now getting some respect and quiet recognition as the founder and CEO of Spectrum Pharmaceuticals (SPPI).
In just 10 years, Dr. Shrotriya has created the company from scratch, literally, to build up what is now a profitable enterprise that has produced two cancer drugs that are already in the market. Although the company it still tiny compared with such industry giants as Amgen (AMGN) and Teva Pharmaceutical Industries (TEVA), Spectrum is on the way to ramping up its revenue and earnings, and expanding its pipeline.
Apart from its anti-cancer drugs Fusilev and Zevalin, Spectrum has 10 other oncology drug candidates that are now in clinical development, two of them in phase 3 clinical trials and several undergoing phase 1 and 2 clinical studies.
“A fast-growing cancer drug company, Spectrum is on track to almost quadruple its revenue, from $74 million in 2010 to our estimated $266 million in 2012,” says Difei Yang, analyst at WallachBeth Capital, who has initiated coverage of Spectrum with a buy rating.
Spectrum turned profitable in 2011 after posting losses in prior years, actually earning $48.5 million, or 84 cents a share, in 2011. For 2012, analysts are forecasting earnings of between $1.37 a share and $1.96.
Right now, one of Spectrum’s two fast-growing cancer drugs – Fusilev, which is indicated for osteosarcoma, and colorectal cancer — is the big revenue driver accounting for 78% of total sales. The drug has benefited partly from a shortage of generic drug rival Leucovirin, notes Yang, caused mainly by manufacturing delays. Sales of Spectrum’s other drug, Zevalin, aimed at treating non-Hodgkin lymphoma, have also been on the rise.
However, Spectrum’s drug pipeline “is not being given much credit” by investors, says Yang, and isn’t reflected in the company’s stock’s price, now at $12 a share, down from its 52-week high of $17.48 hit only last month, on July 9, 2012. Yang figures the stock will climb to a new high, at $20 a share. The “downside appears limited,” he adds.
That’s part of the reason why some investors are convinced that in the current frenzy of mergers and acquisitions in the biotech industry, Spectrum may be the next that will be targeted by one or two of the major pharmaceutical companies. Many of the Big Pharma companies have acknowledged their need to acquire companies with products that could help pep up their lethargic sales and earnings momentum.
“Spectrum could be a very attractive acquisition target for the bigger pharmaceutical companies, such as Abbott Laboratories (ABT), Bristol-Myers Squibb, Eli Lilly (LLY), Merck (MRK), Pfizer (PFE) and Teva,” says one investment manager at a hedge fund specializing in biotech investing. As one of the few profitable biotechs around, Spectrum is an enticing target, he adds, having demonstrated its ability to produce drugs with potentially huge markets. Moreover, some drugs that are in the pipeline have the potential of enhancing and contributing to the company’s oncology revenue.
In the meantime, Spectrum has been busy in the M&A front, as well, seeking acquisitions. It is in the process of completing the acquisition of Allos Therapeutics (ALTH), whose drug, Folotyn, is a small-molecule therapeutic for cancer. The acquisition of Allos is a “positive addition to Spectrum’s cancer franchise,” says Yang.
Spectrum has also signed an exclusive collaboration with Allergan (AGN), a technology-driven global health care company, for the development and commercialization of Apaziquone, an agent aimed at treating non-muscle bladder cancer. Apaziquone is one of Spectrum’s two drugs undergoing phase 3 clinical trials, to determine its safety and efficacy as a potential treatment for bladder cancer.
Allergan paid Spectrum $41.5 million and will make additional payments of up to $304 million based on achieving certain development, regulatory, and commercialization milestones. Allergan will have exclusive rights to the drug in the U.S., Europe, and Canada, while Spectrum will retain the rights in Asia, including China and Japan.
The company declined to comment on the speculation that Spectrum may become a takeover target. But takeover or not, some analysts argue that the stock is definitely attractive based on the prospects of its oncology drugs — and the currently depressed price of its stock, due in part to the bears’ heavy shorting of the stock.
Joseph Pantginis, analyst at Roth Capital Markets, who rates Spectrum a buy, says his positive thesis on the stock is based mainly on fundamentals, among them the anticipated revenue growth from Fusilev as the “key value driver,” and the company’s putting in place the pieces to potentially grow Zevalin sales, as well. At the same time, the company has been able to maintain a strong balance sheet.
So Panginis raised his price target for the stock to $25 a share from $15, despite the massive short interest in the stock (43.4% of shares outstanding). He thinks the bears will have difficulty winning the battle as the company “keeps delivering on its numbers,” including the continued strong Fusilev sales.
He says Spectrum’s projected integration of revenues from Allos Therapeutics’ Folotyn should ramp up the company’s total revenue, and help it maintain a strong financial profile that’s augmented by a clean balance sheet.
Pantginis forecasts Spectrum will earn $2.13 a share on projected revenue of $316.9 million, up from an estimated $1.96 a share in 2012 on sales of $262 million.
It took a while but Spectrum’s forward stride is finally getting some attention. In Deloitte’s most recent ranking of 500 of the fastest growing technology, media, telecom, life sciences, and clean-tech companies, Spectrum ranked No. 23.
Not bad for a little known company whose market capitalization remains relatively small, but growing speedily, from $2 million 10 years ago to $900 million in 2012.
Individual investors have yet to “discover” Spectrum, but the major institutional investors are already invested in the stock, with 204 institutions owning some 90% of the shares outstanding.
Among these major shareholders are several of Wall Street’s blue-chip names, led by Fidelity Management & Research, which owns 11% as of June 2012; Tang Capital Management, which holds a 9.3% stake; BlackRock Institutional Trust, with an 8.1% interest, and Vanguard Group, with 5.6%.
“One of the big reasons we are in the stock is Spectrum’s management led by CEO Shrotriya, whose spirited devotion and passionate dedication to push the company forward have enabled the company to grow rapidly within a brief period of time,” says an investment manager at one of the major institutional investors.
What's it to you little fat man who has absolutely no skin in the SPPI game.....who wishes us good luck and then turns around and stabs us in the back every chance he gets??!!
BTW, who in tarnation is "Rogs??" I actually get rather amused at reading baa.....baaa...babbling idiot, Iome, Yak, Goofy, STS, messages as well as many others who post on this MB. They say laughter is the best medicine there is and they all give me many laughs a day!!
Perhaps they can't buy any because they are in the process of being bought out and they would be trading on insider information!! Ya never know!!
Seriously, hneiman. I'm not BS'n anyone. It's quite obvious that there is pure MANIPULATION going on; especially when I'm looking at all the bids stacking up to BUY at these low prices. Furthermore, why wouldn't BIG PHARMA have their eye on SPPI? All the rest of the stuff is BS from the likes of STS, Goofy, babbling idiot, etc. I truly do believe BIG PHARMA is looking at SPPI......if not, they should be!!
you have bats in your belfry! They could care less about the motley 100,000,000 in Convertible Notes. This is mere peanuts to them, as well as the piddly little lawsuits or even the meek little generic threats to Fusilev!! They know where there is value and they know SPPI is very undervalued. Just depends on who scoops them up first and how much of a bidding war there will be!!
Heck, we may even be bought out before year's end!! W O O P......W O O P!!